Growth factors

H2 2020 Pipeline Review for Beta Nerve Growth Factor - ResearchAndMarkets.com

Retrieved on: 
Friday, October 16, 2020

The "Beta Nerve Growth Factor - Pipeline Review, H2 2020" drug pipelines has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Beta Nerve Growth Factor - Pipeline Review, H2 2020" drug pipelines has been added to ResearchAndMarkets.com's offering.
  • Beta Nerve Growth Factor (Beta NGF or NGF) pipeline Target constitutes close to 10 molecules.
  • The latest report Beta Nerve Growth Factor - Pipeline Review, H2 2020, outlays comprehensive information on the Beta Nerve Growth Factor (Beta NGF or NGF) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.
  • Beta Nerve Growth Factor (Beta NGF or NGF) - Nerve growth factor is a neurotrophic factor involved in the regulation of growth, maintenance, proliferation, and survival of certain target neurons.

Humanigen to Present at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit

Retrieved on: 
Tuesday, September 22, 2020

Humanigen, Inc. , (Nasdaq: HGEN) (Humanigen), announced today that management will present a company overview and business update at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit at 10:50 a.m. EDT, Wednesday, September 23, 2020.

Key Points: 
  • Humanigen, Inc. , (Nasdaq: HGEN) (Humanigen), announced today that management will present a company overview and business update at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit at 10:50 a.m. EDT, Wednesday, September 23, 2020.
  • Archived replay will be available on the Company website for 30 days following the event.
  • We believe that our GM-CSF neutralization and gene-editing platform technologies have the potential to reduce the inflammatory cascade associated with coronavirus infection.
  • You should not place undue reliance on any forward-looking statements, which speak only as of the date of this release.

Savara to Present at the 22nd Annual H.C. Wainwright Annual Investment Conference Being Held Virtually

Retrieved on: 
Wednesday, September 9, 2020

Savara Inc. (Nasdaq: SVRA), an orphan lung disease company, today announced that Savara management will be presenting at the H.C. Wainwright Annual Investment Conference on Wednesday, September 16, 2020 at 3:00 PM EDT/12:00 PM PDT.

Key Points: 
  • Savara Inc. (Nasdaq: SVRA), an orphan lung disease company, today announced that Savara management will be presenting at the H.C. Wainwright Annual Investment Conference on Wednesday, September 16, 2020 at 3:00 PM EDT/12:00 PM PDT.
  • Interested parties can access a live audio webcast on the Investors page of the Savara website at www.savarapharma.com/investors/events-presentations/ .
  • Savara is an orphan lung disease company with a pipeline comprised of three investigational compounds, all of which use an inhaled delivery route.
  • Our lead program, Molgradex, is an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP).

FibroGen to Present at Upcoming Investor Conferences

Retrieved on: 
Tuesday, September 1, 2020

A replay will be available for approximately 30 days.

Key Points: 
  • A replay will be available for approximately 30 days.
  • FibroGen, Inc. is a biopharmaceutical company committed to discovering, developing and commercializing a pipeline of first-in-class therapeutics.
  • The company applies its pioneering expertise in hypoxia-inducible factor (HIF) and connective tissue growth factor (CTGF) biology to advance innovative medicines to treat unmet needs.
  • Roxadustat is also in clinical development for anemia associated with myelodysplastic syndromes (MDS) and for chemotherapy-induced anemia.

Anemia in Chronic Kidney Disease: 2020 Pipeline Research Monitor - ResearchAndMarkets.com

Retrieved on: 
Thursday, August 13, 2020

The "Anemia in Chronic Kidney Disease Pipeline Research Monitor, 2020 - Drugs, Companies, Clinical Trials, R&D Pipeline Updates, Status and Outlook" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Anemia in Chronic Kidney Disease Pipeline Research Monitor, 2020 - Drugs, Companies, Clinical Trials, R&D Pipeline Updates, Status and Outlook" report has been added to ResearchAndMarkets.com's offering.
  • The Anemia in Chronic Kidney Disease pipeline Research Monitor, 2020 report is an analytical research study on the progress achieved by pipeline companies during the year along with its historical development, current status, and outlook.
  • This Anemia in Chronic Kidney Disease pipeline review explores high-potential early to late-stage pipeline projects with a continued focus on new insights, accelerated processes, and pipeline progression.
  • The competitive intelligence report on Anemia in Chronic Kidney Disease presents detailed insights into therapeutic drug pipeline development, industry news, deals, and analysis across the length and breadth of the Anemia in Chronic Kidney Disease pipeline.

Everest Medicines Announces First Patient Dosed in a Phase 1b/2 Study of FGF401 in Combination with Pembrolizumab for the Treatment of Advanced Solid Tumors

Retrieved on: 
Friday, August 7, 2020

FGF401 is an ATP-competitive, reversible-covalent inhibitor of fibroblast growth factor receptor 4, or FGFR4, for which Everest Medicines obtained global development and commercial rights from Novartis AG, or Novartis.

Key Points: 
  • FGF401 is an ATP-competitive, reversible-covalent inhibitor of fibroblast growth factor receptor 4, or FGFR4, for which Everest Medicines obtained global development and commercial rights from Novartis AG, or Novartis.
  • Growing evidence demonstrates that the activation of the FGF19-FGFR4 pathway is associated with the formation of solid tumors.
  • FGF401 is an ATP-competitive, reversible-covalent inhibitor of FGFR4 for which Everest Medicines obtained exclusive global development and commercial rights from Novartis.
  • Everest is developing FGF401 as a potential new treatment for HCC and other solid tumors associated with activation of the FGF19-FGFR4 pathway.

Partner Therapeutics Announces $35 Million Contract with U.S. Department of Defense for Advanced Development and Emergency Use of Leukine® (rhuGM-CSF) for COVID-19 Acute Hypoxemic Respiratory Failure (AHRF)

Retrieved on: 
Tuesday, August 4, 2020

"Leukine has a proven safety profile and there is clinical evidence indicating that it could confer benefit to patients with acute hypoxemia from COVID-19 infection.

Key Points: 
  • "Leukine has a proven safety profile and there is clinical evidence indicating that it could confer benefit to patients with acute hypoxemia from COVID-19 infection.
  • Leukine is FDA-approved for the treatment of acute radiation syndrome (ARS) and is held in the Strategic National Stockpile.
  • "The potential utility for COVID patients highlights Leukine's promise as a broad-spectrum, dual-use medical countermeasure," added McManus.
  • Partner Therapeutics acquired the rights to Leukine in 2018.Leukine is approved by the FDA.

Timothy Morris Joins Humanigen as Chief Operating Officer and Chief Financial Officer

Retrieved on: 
Monday, August 3, 2020

Humanigen, Inc. , (HGEN) (Humanigen), a clinical stage biopharmaceutical company focused on preventing and treating cytokine release syndrome (CRS) with lenzilumab, the companys proprietary Humaneered anti-human granulocyte macrophage-colony stimulating factor (GM-CSF) monoclonal antibody, announced the appointment of Timothy E. Morris to the newly created role of Chief Operating Officer and Chief Financial Officer, effective immediately, reporting to Dr. Cameron Durrant, Chief Executive Officer.

Key Points: 
  • Humanigen, Inc. , (HGEN) (Humanigen), a clinical stage biopharmaceutical company focused on preventing and treating cytokine release syndrome (CRS) with lenzilumab, the companys proprietary Humaneered anti-human granulocyte macrophage-colony stimulating factor (GM-CSF) monoclonal antibody, announced the appointment of Timothy E. Morris to the newly created role of Chief Operating Officer and Chief Financial Officer, effective immediately, reporting to Dr. Cameron Durrant, Chief Executive Officer.
  • Mr. Morris has more than two decades of experience serving in executive roles at public biotechnology companies.
  • He most recently served as Chief Financial Officer of Iovance, leading the companys raise of over $1 billion in equity, including a recent $600 million secondary offering.
  • Mr. Morris has been a member of the Humanigen Board of Directors since 2016.

Long-Lasting VEGF Blockers and Compounds With VEGF Bring the Quest for the Ideal Retinal Drug a Step Closer

Retrieved on: 
Tuesday, July 28, 2020

In 2018, ~2.4m people in the US had DME, of that only ~70% got diagnosed and treated.

Key Points: 
  • In 2018, ~2.4m people in the US had DME, of that only ~70% got diagnosed and treated.
  • Anti-VEGFs lead the DME market due to its proven efficacy as compared to steroids, making it a premium priced segment.
  • The late stage pipeline comprises of long-lasting VEGF blockers and compounds with VEGF-independent mechanisms such as Tie-2/Angiopoietin pathway modulators and integrin inhibitors.
  • In the coming decade, DME treatment is likely witness a paradigm shift from invasive injectable treatments to non-invasive options.

Exelixis Announces Initiation of CONTACT-03 Phase 3 Pivotal Trial of Cabozantinib in Combination With Atezolizumab in Previously Treated Metastatic Renal Cell Carcinoma

Retrieved on: 
Monday, July 20, 2020

Patients will be randomized 1:1 to the experimental arm of cabozantinib in combination with atezolizumab or the control arm of cabozantinib alone.

Key Points: 
  • Patients will be randomized 1:1 to the experimental arm of cabozantinib in combination with atezolizumab or the control arm of cabozantinib alone.
  • CABOMETYX in combination with atezolizumab is not indicated for metastatic renal cell carcinoma.
  • On January 30, 2017, Exelixis and Takeda jointly announced an exclusive licensing agreement for the commercialization and further development of cabozantinib indications in Japan.
  • Markedly increased amounts of messenger RNAs for vascular endothelial growth factor and placenta growth factor in renal cell carcinoma associated with angiogenesis.